ϟ
DOI: 10.1056/nejmoa1814213
¤ OpenAccess: Bronze
This work has “Bronze” OA status. This means it is free to read on the publisher landing page, but without any identifiable license.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia,Ingrid A. Mayer,Linda T. Vahdat,Sara M. Tolaney,Steven J. Isakoff,Jennifer R. Diamond,Joyce O’Shaughnessy,Rebecca Moroose,Alessandro D. Santin,Vandana G. Abramson,Nikita Shah,Hope S. Rugo,David M. Goldenberg,Ala M Sweidan,Robert Iannone,Sarah A. Washkowitz,Robert M. Sharkey,William A. Wegener,Kevin Kalinsky
Medicine
Metastatic breast cancer
Triple-negative breast cancer
2019
Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody–drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors.
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer” is a paper by Aditya Bardia Ingrid A. Mayer Linda T. Vahdat Sara M. Tolaney Steven J. Isakoff Jennifer R. Diamond Joyce O’Shaughnessy Rebecca Moroose Alessandro D. Santin Vandana G. Abramson Nikita Shah Hope S. Rugo David M. Goldenberg Ala M Sweidan Robert Iannone Sarah A. Washkowitz Robert M. Sharkey William A. Wegener Kevin Kalinsky published in 2019. It has an Open Access status of “bronze”. You can read and download a PDF Full Text of this paper here.